Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department

Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Jan 26, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on finding a better way to increase the number of adults who get vaccinated against the human papilloma virus (HPV) in emergency departments (EDs). Researchers believe that the ED could be a good place to offer vaccinations to adults aged 18 to 45 who haven't received the HPV vaccine or haven't completed the vaccination series. The study will test a new program that aims to provide HPV vaccinations to two groups: younger adults aged 18 to 26, for whom the vaccine is widely recommended, and older adults aged 27 to 45, who may still benefit from the vaccine depending on individual discussions with their healthcare providers.

To be eligible for this study, participants need to be between 18 and 45 years old, in good health as determined by an ED doctor, and not currently infected with certain high-risk HPV strains. However, individuals who are pregnant, have abnormal HPV test results, or are experiencing mental confusion or fever will not be included. If you choose to participate, you can expect to receive more information about the HPV vaccine and how it can help protect against certain cancers. The study aims to make it easier for adults to get vaccinated while they are already at the ED for other reasons.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • aged 18-45 years old
• • in good functional capacity, as determined by the ED-attending clinician
• • no known infection with HPV high risk strain types 6, 11, 16 and 18.
• Exclusion Criteria:
• • will not receive vaccine if participants lack mental clarity and if running a fever or in some pain.
• • Patients aged \<18 or \> 45 years of age.
• • Female patients with abnormal HPV results (including those with the high-risk HPV strain types 6, 11, 16, and 18) as determined by a previous PAP smear test or HPV test.
• • Female patients who are known to be pregnant.
• • Male patients with known cases of HPV-associated infections will also be excluded from the study

Trial Officials